Diagnostic Algorithm Pipeline
Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.
Low Ejection Fraction
Granted FDA Breakthrough Device Designation
Phase: Validation
Pulmonary Hypertension
Granted FDA Breakthrough Device Designation
Phase: Pre-Submission
Hyperkalemia
Granted FDA Breakthrough Device Designation
Phase: Development
Cardiac Amyloidosis
Phase: Development
Atrial Fibrillation in Normal Sinus Rhythm
Phase: Development
Hypertrophic Cardiomyopathy
Phase: Development
Myocarditis
Phase: Development
Aortic Stenosis
Phase: Development
Early Stage Development Programs
Phase: Development
Interventional EP Product Pipeline
Anumana also has a rich pipeline of AI / ML driven products for use in the interventional electrophysiology (EP) setting.
Hardware Agnostic AI/ML-based EAM Software
Phase: Authorization
EP Case Review Software
FDA Clearance Not Required
Phase: Submission
Signal Identification Software
Phase: Validation
Early Stage Development Programs
Phase: Development
Partner with us!
We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to hello@anumana.ai
@2023 anumana, Inc. All rights reserved.